Health Canada has authorized the first made-in-Canada generic alternative to Ozempic, a major development expected to improve affordability and access for Canadians managing Type 2 diabetes and weight loss.
The newly approved medication is a generic semaglutide injection produced by Apotex, Canada’s largest generic drug manufacturer.
Semaglutide is the active ingredient in both Ozempic and Wegovy, medications manufactured by Novo Nordisk.
Health Canada said the Apotex product met federal standards for safety, quality and effectiveness following a detailed regulatory review.
The approval follows the expiration of Novo Nordisk’s Canadian patent for semaglutide earlier this year, opening the door for generic alternatives.
What Are GLP-1 Medications?
Semaglutide belongs to a class of medications known as GLP-1 receptor agonists.
These medications help regulate blood sugar levels, slow digestion and reduce appetite, making them widely used for treating Type 2 diabetes and obesity.
The Apotex injectable is approved for once-weekly treatment of adults with Type 2 diabetes to help manage blood sugar levels.
Health Canada is also currently reviewing seven additional generic semaglutide submissions from other pharmaceutical companies, with more approvals expected in the coming months.
Earlier this year, Indian pharmaceutical company Dr. Reddy’s Laboratories became the first firm to receive Canadian authorization for a generic semaglutide injection.
Lower Costs Expected for Patients
Health Canada says generic drugs are typically 45 to 90 per cent cheaper than brand-name medications, potentially creating major savings for patients and the health-care system.
According to Ontario-based virtual care platform Ogaei, patients without insurance coverage can spend more than $3,000 annually on Ozempic treatment.
Many private insurance providers already allow pharmacists to substitute approved generic medications unless doctors specifically request brand-name products.
Growing “Ozempic Effect” on Food Industry
Experts say the growing use of GLP-1 medications is also beginning to impact consumer eating habits and the food industry.
Sylvain Charlebois, senior director of the Agri-Food Analytics Lab at Dalhousie University, said appetite-suppressing medications are reducing demand for calorie-dense foods such as chips, fries and processed snacks.
Research published in the Journal of Marketing Research found U.S. households with at least one GLP-1 user reduced grocery spending by more than five per cent within six months, with the largest reductions seen in processed snack foods.
Side Effects and Long-Term Concerns
Medical experts caution that GLP-1 medications are not without risks.
Common short-term side effects include nausea, vomiting, diarrhea, constipation, bloating, fatigue and headaches.
Potential long-term risks may include muscle loss, reduced bone density, gallbladder disease, pancreatitis and kidney injury in rare cases.
Health experts also warn many patients may regain weight after stopping treatment unless healthy diet and exercise habits are maintained.
Despite the concerns, the approval of lower-cost generics is expected to significantly expand access to semaglutide-based treatments across Canada.